



NEWS RELEASE

EXMCEUTICALS INC. ANNOUNCES PILOT PROJECT IN MALAWI

VANCOUVER, BRITISH COLUMBIA – February 12, 2019 – EXMceuticals Inc. (CSE: [EXM](#)) (“**EXM**” or the “**Company**”) is pleased to announce that the Ministry of Finance, Economic Planning and Development of Malawi, together with the Special Projects Committee of Malawi and other government agencies, have provided EXM with a provisional letter providing a provisional authorization for EXM’s Malawi subsidiary, Ceuticals Farming Limited (“**EXM Malawi**”), to proceed with its cannabis project of cultivating cannabis and exporting cannabis extracted ingredients. EXM Malawi will be operating under the provisional authorization pending the issuance of a formal license which is currently expected to occur in next few months following the opening of the next session of the Malawi Parliament.

Under the provisional authorization, EXM Malawi, proposes to cultivate an initial 50 hectares (120 acres) of cannabis and establish the required extraction capacities and ancillary services. Upon receipt of the formal license, EXM Malawi intends to establish over 800 hectares (2000 acres) of cannabis cultivation and processing capacity in Malawi.

“We are very happy to have won the trust and support of government members and officials of Malawi. This makes us very confident in the future of our operations in the country”, said Michel Passebon, Chief Executive Officer of EXMceuticals Inc.

“We are very excited to establish a strong foothold in Malawi and work with our partners”, said John Anderson, Chairman of EXMceuticals Inc. “This particular operation will target rapid development and production this year and is a major step forward for EXM.”

About EXM

EXM’s activities are focused on the sustainable cultivation of cannabis and hemp, and the production of pharmaceutical grade, psychotropic and non-psychotropic cannabis and hemp ingredients for the pharmaceutical, therapeutical and nutraceutical industries. The Company proposes to export the extracted ingredients to international markets.

EXM, through its subsidiary and in-country partner, holds the rights to a cannabis license in the Kuba Kingdom, Mweka, Kasai Province, Democratic Republic of Congo, and the rights to a land concession for the cultivation of cannabis and hemp, and processing and export of high-grade pharmaceutical cannabinoid ingredients.

EXM is in the process of applying for a license in Portugal for the establishment of a laboratory for research, a nursery, and a center for processing and distribution. In addition to its more scientific mandate, the facility is proposed to be used by EXM as its base for distribution in the EU. EXM has initiated discussions with its university partners, Universidade Nova de Lisboa and Universidade Lusofona, and the government licensing authorities to obtain research & development, import, transformation and export licenses, which would enable EXM to establish its research and lab facilities and confirm Portugal as the trans-shipment point for North America and Europe. Pending receipt of the license, EXM proposes to proceed with its R&D program, lab work and testing under the licenses that its university partners have already obtained.

EXM has submitted applications and undertaken negotiations with local governments and partners in Ethiopia, Uganda, Malawi, Zambia and Burundi, in order to obtain licences to permit the cultivation of cannabis and hemp, as well as the processing, transformation and export of psychotropic and nonpsychotropic cannabinoid ingredients. In Ethiopia, EXM is in its final stage of negotiation with the government for an agro-industrial park, of 4,000 hectares (10,000 acres) encompassing a free trade zone. In addition, EXM is in the process of obtaining a license in each of Uganda and Malawi, in partnership with a large local agro producer, to enable the import of cannabis grown at other EXM sites in Africa.

Please visit www.exmceuticals.com for more information.

ON BEHALF OF THE BOARD OF DIRECTORS OF EXMCEUTICALS INC.

Michel Passebon, Chief Executive Officer and Director

For further information contact:

John Anderson, Chairman
Telephone: +1 403-870-1562
Email: john@exmceuticals.com

Cayvan Consulting
Telephone: +1 345-232-1569
Email: info@cayvan.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “will be”, “expected”, “proposes”, “intends” or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements regarding the Company’s business operations, including the pilot project in Malawi and obtaining licences, are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of EXM to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. EXM will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.